Abstract
This paper looks at the ethical, legal, and social issues (ELSI) associated with commercialization and patenting through the lens of nutrigenomics. These are two areas have generated a great deal of ELSI literature, although very little specific to nutrigenomic research. Nutrigenomic researchers seem likely to face the same patent concerns as those associated with gene patents more generally--specifically, that patents will hurt research and the distribution and uptake of useful technologies. Likewise, there is concern that commercialization pressure will lead to the inappropriate and premature implementation of nutrigenomic services. This paper concludes that while the patenting issues do not seem unique or particularly worrisome in the context of nutrigenomics, the early commercialization of testing is cause for concern and worthy of careful policy consideration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
